Inhibrx Biosciences (INBX) Enterprise Value: 2023-2025
Historic Enterprise Value for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $334.8 million.
- Inhibrx Biosciences' Enterprise Value rose 1002.64% to $334.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.9 million, marking a year-over-year decrease of 197.47%. This contributed to the annual value of $70.3 million for FY2024, which is 125.31% up from last year.
- Latest data reveals that Inhibrx Biosciences reported Enterprise Value of $334.8 million as of Q3 2025, which was up 1,576.26% from $20.0 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Enterprise Value ranged from a high of $334.8 million in Q3 2025 and a low of -$277.9 million during Q4 2023.
- Its 3-year average for Enterprise Value is $18.0 million, with a median of $20.0 million in 2025.
- Data for Inhibrx Biosciences' Enterprise Value shows a peak YoY spiked of 1,002.64% (in 2025) over the last 5 years.
- Inhibrx Biosciences' Enterprise Value (Quarterly) stood at -$277.9 million in 2023, then surged by 125.31% to $70.3 million in 2024, then spiked by 1,002.64% to $334.8 million in 2025.
- Its Enterprise Value stands at $334.8 million for Q3 2025, versus $20.0 million for Q2 2025 and -$14.0 million for Q1 2025.